Abiopharma

🔍 HERBST SETH (Director)

Company: DYADIC INTERNATIONAL INC (DYAI)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 21,552 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 202,311.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 21,552 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Acquired 50,000 shares of Stock Option at $0.94 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 39,894 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 39,894.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F2: Annual grant of stock options.
• F3: Annual grant of restricted stock units.
• F4: The restricted stock units will be settled 100% in Issuer's common stock when vested upon the first anniversary of the date of grant, subject to continued service as a member of the board of directors.
• F5: The restricted stock units previously issued and vested upon the first anniversary of the date of grant, subject to continued service as a member of the board of directors, were settled 100% in Issuer's common stock.